Small molecule · Modulator of mu-opioid receptor (OPRM1) · developed by Indivior
Buprenorphine and naloxone is a sublingual film combining buprenorphine, a partial agonist at the mu-opioid receptor and antagonist at the kappa-opioid receptor, with naloxone, a mu-opioid receptor antagonist. It is used in the treatment of opioid dependence, with counseling and psychosocial support as part of a complete treatment plan.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 22, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03993392 | Phase 4 | Opioid-use Disorder | Completed | INDV |
| NCT01846455 | Phase 4 | Hepatic Failure | Completed | INDV |
| NCT02357901 | Phase 3 | Opioid Dependence | Completed | INDV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Hepatitis C Infection With Hepatic ComaHepatic FailureHepatic ImpairmentOpioid DependenceOpioid Related DisordersOpioid-use Disorder
Updated Oct 18, 2026.